Company Product Description Indication Status
Amgen Inc., of Thousand Oaks, Calif. Sotorasib KRASG12C inhibitor Non-small-cell lung cancer FDA granted breakthrough therapy designation
Beigene Ltd., of Beijing Blincyto (blinatumomab)  CD3 modulator; B-lymphocyte antigen CD19 modulator Relapsed or refractory B-cell precursor acute lymphoblastic leukemia  Approval granted in China
Cerecor Inc., of Rockville, Md. CERC-007 Monoclonal antibody targeting IL-18 Relapsed or refractory multiple myeloma IND application accepted by FDA
Cyxone AB, of Stockholm Rabeximod Anti-rheumatic compound COVID-19 infection therapy Regulatory approval granted to begin phase II trial in Poland
Henlius Biotech Inc., of Shanghai HLX-03 Biosimilar to Humira (adalimumab, Abbvie Inc.) Rheumatoid arthritis, ankylosing spondylitis and plaque psoriasis  Approval granted in China
ITM Isotopen Technologien München AG, of Garching, Germany Gegant Germanium-68/Gallium-68 generator Various cancers FDA issued the drug master file
Ix Biopharma Ltd., of Singapore Wafermine Sublingual ketamine wafer Pain EMA endorsed design of pivotal phase III studies
Takeda Pharmaceutical Co. Ltd., of Tokyo Takhzyro (lanadelumab) Kallikrein blocker Hereditary angioedema Approval granted in China
Turning Point Therapeutics Inc., of San Diego Repotrectinib Macrocyclic tyrosine kinase inhibitor of ROS1, TRK and ALK ROS1-positive metastatic non-small-cell lung cancer FDA granted breakthrough therapy designation for the treatment of patients who have not been treated with a ROS1 tyrosine kinase inhibitor 


For more information about individual companies and/or products, see Cortellis.